Director

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Institution	Shares	Value	Change
BlackRock, Inc.	22,252,930	$739M	INCREASED
STATE STREET CORP	8,649,766	$287M	INCREASED
VANGUARD PORTFOLIO MANAGEMENT LLC	8,273,979	$275M	NEW
VANGUARD CAPITAL MANAGEMENT LLC	6,603,258	$219M	NEW
Soleus Capital Management, L.P.	4,029,319	$134M	INCREASED

Insider	Type	Shares	Date
Laurence N Charney (Director)	AWARD	8,325	2026-06-11
Yann Echelard (Director)	AWARD	8,325	2026-06-11
Kenneth Hoberman (Director)	AWARD	8,325	2026-06-11
Daniel Hume (Director)	AWARD	8,325	2026-06-11
Sagar Lonial (Director)	AWARD	8,325	2026-06-11

TG Therapeutics, Inc. (TGTX) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades